Michael Makris/LinkedIn
Sep 3, 2025, 03:05
Insights from Michael Makris: FAERS Reveals Thrombotic Events for Marstacimab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, has shared a post on LinkedIn:
“The FDA Adverse Event Reporting System (FAERS) has launched a public dashboard. I thought I would give it a try by looking at what has been reported so far for the ‘rebalancing’ agents.
I was interested to see 3 thrombotic events for marstacimab (Hympavzi). I do not know if one of these is the thrombotic event reported at EAHAD 2025, or whether that was a 4th event. My contacts tell me that the event reported at EAHAD 2025 was in a patient outside the USA.”
Read for more.
Stay informed with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis